siRNA-mediated inhibition of SREBP cleavage-activating protein reduces dyslipidemia in spontaneously dysmetabolic rhesus monkeys.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Metabolism: Clinical and Experimental

• Publication date

  2017-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.metabol.2017.02.015PMID 28521874
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey[S]

  2016cited by this paper
• New insights into the pathophysiology of dyslipidemia in type 2 diabetes.

  2015cited by this paper
• Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

  2015cited by this paper
• PCSK9 and triglyceride-rich lipoprotein metabolism

  2015cited by this paper
• Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat

  2014cited by this paper
• Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

  2014cited by this paper
• Diabetic dyslipidemia.

  2014cited by this paper
• Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

  2014cited by this paper
• Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins.

  2014cited by this paper
• SREBP: a novel therapeutic target.

  2013cited by this paper
• Involvement of toll-like receptor 2 and 4 in association between dyslipidemia and osteoclast differentiation in apolipoprotein E deficient rat periodontium

  2013cited by this paper
• Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy

  2013cited by this paper
• Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations

  2013cited by this paper
• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

  2013cited by this paper
• The biology and therapeutic targeting of the proprotein convertases

  2012cited by this paper
• Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass

  2012cited by this paper
• Demonstration of diet-induced decoupling of fatty acid and cholesterol synthesis by combining gene expression array and 2H2O quantification.

  2012cited by this paper
• An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

  2012cited by this paper
• Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

  2012cited by this paper
• The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals.

  2012cited by this paper
• Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

  2012cited by this paper
• Mechanisms of diabetic dyslipidemia: relevance for atherogenesis.

  2012cited by this paper
• Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people.

  2011cited by this paper
• Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques.

  2011cited by this paper
• Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects

  2011cited by this paper
• Biodistribution of Small Interfering RNA at the Organ and Cellular Levels after Lipid Nanoparticle-mediated Delivery

  2011cited by this paper
• Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue

  2011cited by this paper
• Headspace analyses of acetone: a rapid method for measuring the 2H-labeling of water.

  2010cited by this paper
• A new method for measurement of total plasma PCSK9: clinical applications

  2010cited by this paper
• Beyond LDL cholesterol, a new role for PCSK9.

  2010cited by this paper
• Lessons learned from candidate drug attrition.

  2010cited by this paper
• Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis

  2010cited by this paper
• Sterol regulatory element binding proteins (SREBPs): controllers of lipid synthesis and cellular uptake.

  2009cited by this paper
• Genetic and metabolic determinants of plasma PCSK9 levels.

  2009cited by this paper
• Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2*

  2008cited by this paper
• Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c*

  2006cited by this paper
• Severe Hypercholesterolemia in Four British Families With the D374Y Mutation in the PCSK9 Gene: Long-Term Follow-Up and Treatment Response

  2005cited by this paper
• Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9

  2004cited by this paper
• Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mices⃞s⃞ The online version of this article (available at http://www.jlr.org) contains one supplemental table. Published, JLR Papers in Press, August 1, 2003. DOI 10.1194/jlr.M300203-JLR200

  2003cited by this paper
• Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

  2003cited by this paper
• SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.

  2002cited by this paper
• Clinical review 124: Diabetic dyslipidemia: causes and consequences.

  2001cited by this paper
• SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation.

  2001cited by this paper
• Diabetic Dyslipidemia: Causes and Consequences

  2001cited by this paper
• Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets.

  2000cited by this paper
• Increased Levels of Nuclear SREBP-1c Associated with Fatty Livers in Two Mouse Models of Diabetes Mellitus*

  1999cited by this paper
• Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2.

  1998cited by this paper
• Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein.

  1996cited by this paper
• Changes in lipoprotein concentrations during the development of noninsulin-dependent diabetes mellitus in obese rhesus monkeys (Macaca mulatta).

  1991cited by this paper
• Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis

  1991cited by this paper
• A receptor-mediated pathway for cholesterol homeostasis.

  1986cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Comparison between Fractional Turnover Rate of Endogenous Plasma Triglycerides and of Intralipid® (Intravenous Fat Tolerance Test) in Man *

  1974cited by this paper

• Genomic medicine in hepatology: mechanisms and liver treatment strategies

  2025cites this paper
• PCSK9 in metabolism and diseases.

  2024cites this paper
• The interaction between lipid and vitamin D3 impacts lipid metabolism and innate immunity in Chinese mitten crabs Eriocheir sinensis.

  2024cites this paper
• Regulation and targeting of SREBP-1 in hepatocellular carcinoma

  2023cites this paper
• Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis

  2022cites this paper
• PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis

  2020cites this paper
• Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats

  2020cites this paper
• Triglyceride-Rich Lipoproteins.

  2018cites this paper
• Research advances in metabolism 2017.

  2018cites this paper
• Developmental and extrahepatic physiological functions of SREBP pathway genes in mice.

  2017cites this paper